Emyria Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EMD.AX research report →
Price Chart
About the company
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs. Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions.
- CEO
- Gregory Hutchinson
- IPO
- 2020
- Employees
- 6
- HQ
- Leederville, WA, AU
Get TickerSpark's AI analysis on EMD.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $26.92M
- P/E
- -5.80
- Fwd P/E
- 7.83
- PEG
- 0.08
- P/S
- 12.37
- P/B
- 2.64
- EV/EBITDA
- -4.38
- Div Yield
- 0.00%
- Gross Margin
- -56.70%
- Op Margin
- -186.26%
- Net Margin
- -209.09%
- ROE
- -52.26%
- ROIC
- -31.93%
Latest fiscal year · YoY change
- Revenue
- $1.39M-36.7%
- Gross Profit
- $24.48K+114.6%
- Op Income
- $-2,645,242
- Net Income
- $-3,142,758+72.6%
- EPS
- $-0.01+78.1%
- OCF Growth
- +36.9%
- FCF Growth
- +38.8%
- 52W High
- $0.08
- 52W Low
- $0.04
- 50D MA
- $0.04
- 200D MA
- $0.05
- Beta
- 0.03
- RSI (14)
- 53
- Avg Volume
- 1.08M
No earnings-call transcripts are available for EMD.AX yet.
- Free Float
- 74.2%
- Shares Outstanding
- 572.76M
- Float Shares
- 424.86M
Our EMD.AX coverage
Recent articles, reports, and earnings notes.
No research on EMD.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EMD.AX report →